Main > ONCOLOGY (**) > Leukemia>Lymphocytic>Chronic *** > Treatment > USA. A. Ibrutinib ***
USA. A. Ibrutinib ***'s subsections
(*) CA Approval Date : 2016. 07.20>
(*) USA Approval Date: 2014. 07.28>
(*) USA Approval Date: 2016. 03.04>
BTK: Bruton s Tyrosine Kinase>
Company
Marketing in EU:
Mechanism: BTK Inhibition
Patent>Assignee; Claims; No.; Etc.
Patent>Total USA No.: 40
Patent>UpDate: 2018. 11.06.
TradeMark
TradeMark Web-Site
USA. A. Ibrutinib ***'s products
This section has no products